about
The Influence of Sub-Unit Composition and Expression System on the Functional Antibody Response in the Development of a VAR2CSA Based Plasmodium falciparum Placental Malaria VaccineDifferential induction of functional IgG using the Plasmodium falciparum placental malaria vaccine candidate VAR2CSAPlacental Sequestration of Plasmodium falciparum Malaria Parasites Is Mediated by the Interaction Between VAR2CSA and Chondroitin Sulfate A on Syndecan-1Geographical and temporal conservation of antibody recognition of Plasmodium falciparum variant surface antigens.Epitope mapping and topographic analysis of VAR2CSA DBL3X involved in P. falciparum placental sequestration.Structural insight into epitopes in the pregnancy-associated malaria protein VAR2CSAPlasmodium falciparum transcriptome analysis reveals pregnancy malaria associated gene expression.Identification of glycosaminoglycan binding regions in the Plasmodium falciparum encoded placental sequestration ligand, VAR2CSAAn upstream open reading frame controls translation of var2csa, a gene implicated in placental malaria.Multiple var2csa-type PfEMP1 genes located at different chromosomal loci occur in many Plasmodium falciparum isolatesSeveral domains from VAR2CSA can induce Plasmodium falciparum adhesion-blocking antibodies.Full-length recombinant Plasmodium falciparum VAR2CSA binds specifically to CSPG and induces potent parasite adhesion-blocking antibodies.The chondroitin sulfate A-binding site of the VAR2CSA protein involves multiple N-terminal domainsSevere malaria is associated with parasite binding to endothelial protein C receptorEvidence for the involvement of VAR2CSA in pregnancy-associated malaria.Identification and characterization of B-cell epitopes in the DBL4ε domain of VAR2CSABacterial superglue enables easy development of efficient virus-like particle based vaccines.Baculovirus-expressed constructs induce immunoglobulin G that recognizes VAR2CSA on Plasmodium falciparum-infected erythrocytes.Plasmodium falciparum expressing domain cassette 5 type PfEMP1 (DC5-PfEMP1) bind PECAM1.Cytoadhesion of Plasmodium falciparum-infected erythrocytes to chondroitin-4-sulfate is cooperative and shear enhanced.Positive selection of Plasmodium falciparum parasites with multiple var2csa-type PfEMP1 genes during the course of infection in pregnant women.Protective Antibodies against Placental Malaria and Poor Outcomes during Pregnancy, BeninEthnomedicinal survey and in vitro anti-plasmodial activity of the palm Borassus aethiopum Mart.Identification of a Major Dimorphic Region in the Functionally Critical N-Terminal ID1 Domain of VAR2CSA.A Novel Virus-Like Particle Based Vaccine Platform Displaying the Placental Malaria Antigen VAR2CSA.Changes in var gene mRNA levels during erythrocytic development in two phenotypically distinct Plasmodium falciparum parasitesStructural and functional insight into how the Plasmodium falciparum VAR2CSA protein mediates binding to chondroitin sulfate A in placental malaria.Plasmodium falciparum associated with severe childhood malaria preferentially expresses PfEMP1 encoded by group A var genes.Multilaboratory approach to preclinical evaluation of vaccine immunogens for placental malaria.Targeting Human Cancer by a Glycosaminoglycan Binding Malaria Protein.Differences in human antibody reactivity to Plasmodium falciparum variant surface antigens are dependent on age and malaria transmission intensity in northeastern TanzaniaAdhesion of Plasmodium falciparum infected erythrocytes in ex vivo perfused placental tissue: a novel model of placental malaria.Induction of adhesion-inhibitory antibodies against placental Plasmodium falciparum parasites by using single domains of VAR2CSA.Clinical development of placental malaria vaccines and immunoassays harmonization: a workshop report.Bacterial superglue generates a full-length circumsporozoite protein virus-like particle vaccine capable of inducing high and durable antibody responses.Human pregnancy-associated malaria-specific B cells target polymorphic, conformational epitopes in VAR2CSA.Utilizing nanobody technology to target non-immunodominant domains of VAR2CSA.Can any lessons be learned from the ambiguous glycan binding of PfEMP1 domains?Pre-clinical and clinical development of the first placental malaria vaccine.Burkitt lymphoma expresses oncofetal chondroitin sulfate without being a reservoir for placental malaria sequestration.
P50
Q27300745-FB3C651A-0A65-4431-8A3A-A908B064C6CAQ27349502-80EE4276-7E10-4EEA-9E68-6EAC9066D7D9Q27973758-5575199A-157C-47EB-A93C-7AA5F4A6869BQ31064176-95AC4349-3EC2-4ACD-9BFF-3A52538C846CQ33263953-6061EFFC-E899-471E-A265-6DA7FBD4071BQ33320197-25AF903B-3ED7-4902-A2EC-CB833006B469Q33325481-CD296854-41E4-42FE-B724-707599F3178FQ33340867-2A566EBE-64A9-45BE-9A1E-DFDCC0BC62F7Q33396980-8A19C965-3E02-4215-ADD8-4B6777D2E731Q33494832-85372C0C-D50C-4741-B533-DE0B045D4BA1Q33634689-D075644F-80E5-4213-9E29-77845E31ADFBQ34095324-16166CB3-4D5A-4530-AECD-6D8C6DDD1186Q34170375-B3ECEF58-168C-4E4E-8148-FD2FC1F72AC1Q34348881-609F618A-9295-42B0-9EC0-20C8B5558435Q34364093-15CA2185-02FA-4FC9-B083-E6C8F06AB9C9Q34412101-6B2BFBF6-B373-48AE-B673-A621DFE5A676Q34523734-A4BD44BE-9A89-4FF5-B29A-9769481A8E03Q34721210-3E29330F-4A8A-41FD-A027-BBD552F71C72Q34853037-225485E2-22D8-4206-8706-0216D938C4A1Q34876859-DCCD175F-EE9F-4180-A7E2-D1DEE17260ADQ34988334-CCD06D57-A65A-4606-8344-8C99C202C650Q35546075-87B840BA-4EEF-448E-A029-2833479BB19CQ35780516-91E99D6A-A16A-42BE-8F42-8A63284A8578Q35783076-C7B23F46-CFED-4AA1-8842-ABABE4725503Q35850159-038F15C5-7A50-48B1-A1CF-65201B5AD231Q35865612-C817002F-0E4F-4579-A160-E61BA15E2997Q36078717-45EB3731-FEC4-4C21-A156-E3D9F4470AF2Q36399515-69EB6415-C025-439B-9169-C39059A7D890Q36558721-8DA4F507-42FD-42A7-A384-A3B415A1DEBDQ36683860-BC4B53EF-BE31-494A-8F7C-CCE2FB646DFEQ36710616-3BEBFC32-20F7-4BF6-B9AC-60BC715BB055Q36938125-511B3A81-422E-4380-BD28-86481CD64CF9Q37204480-AA4DA134-0BFA-41CD-B003-87FAA4D0B305Q37263318-4A2FA4C6-1B71-4BA3-81CF-4024044C2BB4Q37402846-78E38585-3BC4-4BBA-9B73-6D4A288978FCQ37426131-E657086C-80D2-4994-9B02-6420F37B6BA1Q37499204-8A6C65BB-6406-4E3E-9F54-5D5E3F6E263CQ37699950-7CC2F4FC-AB07-41A9-8280-2692F92A2A32Q38691920-3D14AD47-201C-4EB6-9388-62B39F127EC4Q38725258-1CF49C4D-C471-4943-9A3C-FD0D1FB79D62
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Morten Agertoug Nielsen
@ast
Morten Agertoug Nielsen
@en
Morten Agertoug Nielsen
@es
Morten Agertoug Nielsen
@nl
Morten Agertoug Nielsen
@sl
type
label
Morten Agertoug Nielsen
@ast
Morten Agertoug Nielsen
@en
Morten Agertoug Nielsen
@es
Morten Agertoug Nielsen
@nl
Morten Agertoug Nielsen
@sl
altLabel
Morten A Nielsen
@en
prefLabel
Morten Agertoug Nielsen
@ast
Morten Agertoug Nielsen
@en
Morten Agertoug Nielsen
@es
Morten Agertoug Nielsen
@nl
Morten Agertoug Nielsen
@sl
P106
P1153
7402929540
P21
P214
5412148390881710830009
P31
P496
0000-0003-2668-4992